---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-037633"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:35:09.035004+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD Q3 revenue $20.9M, net loss $29.0M; cash drops to $27.1M

## Summary
- Net revenue $20.9M, down 18% YoY; net loss $29.0M ($3.13/sh) vs $47.4M loss YoY.
- Operating expenses cut $22.2M YoY to $37.9M; product gross margin 82% vs 78%.
- ANNOVERA revenue $10.4M (-$1.4M YoY), Rx up 10% YoY; IMVEXXY $6.9M; BIJUVA $2.7M.
- Cash $27.1M at Sep 30, down from $65.1M at Dec 31; post-quarter $7M investment from Rubric Capital.
- Net debt and preferred stock liability $117.1M; no earnings call due to strategic alternatives review.

## SEC filing metadata
- accession: 0001564590-22-037633
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000156459022037633/0001564590-22-037633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000156459022037633/txmd-8k_20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-037633
- JSON: https://secwatch.observer/filing/0001564590-22-037633.json
- Plain text: https://secwatch.observer/filing/0001564590-22-037633.txt

## Key facts
- Earnings Releases
  TherapeuticsMD, Inc. reported the third quarter ended September 30, 2022 results: revenue $20.9 million, net income $29.0 million, EPS $3.13 per basic and diluted share.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $20.9 million
  - Net income: $29.0 million
  - EPS: $3.13 per basic and diluted share
  - Result: reported results
  source text: Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000156459022037633/0001564590-22-037633-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.